Newsbenzinga
Ionis to Seek Expedited FDA Review for ALS Drug
· Published
Article summary
Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.
An excerpt from the original article.
Comments —
Loading comments…